Rankings
▼
Calendar
TELO FY 2022 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$854,147
Net Income
-$854,147
EPS (Diluted)
$-0.03
Cash Flow
Operating Cash Flow
-$468,661
Free Cash Flow
-$468,661
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$48,730
Total Liabilities
$986,008
Stockholders' Equity
-$937,278
Cash & Equivalents
$1,419
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$854,147
-$138,131
-518.4%
Net Income
-$854,147
-$138,131
-518.4%
← FY 2021
All Quarters
Q1 2022 →